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  The canine transmissible venereal tumor (CTVT) is found 
mainly in dogs’ sexual organs. Currently, it is widely accepted 
that all samples of CTVT show similar histopathological 
characteristics and share common genetic alterations. Despite 
the common genetic origin of CTVT, mutations in the P53 
gene have been reported. In this study, we proposed that 
tumor samples can be genetically grouped using this gene. 
The presence of different subgroups of CTVT was determined 
in Mexican dogs using the TP53 gene sequence in CTVT 
samples. Four new polymorphisms were found and therefore, 
the CTVT samples were classified in five subgroups.
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The canine transmissible venereal tumor (CTVT) is 
characterized by the vertical propagation of tumoral cells 
from an affected individual to a healthy one. Although 
CTVT is mainly found in the sexual organs of female and 
male dogs, it can become highly invasive to other tissues 
[7]. Metastasis occurs in low frequency and the tumors 
generally respond to antineoplasic treatment [1].
Several findings have highlighted that CTVT arose from 
an ancestral neoplasic cell, coming from a single host, 
through successions of selection and clonal expansion 
[3,8]. Accordingly, worldwide samples of CTVT show 
closely related histopathological characteristics and share 
common genetic alterations such as aneuploid karyotype 
with the presence of 58 to 59 chromosomes and a particular 
long interspersed nuclear element (LINE-1) insertion near 
c-myc oncogene [4].
Despite the common origin of CTVT, tumor samples 
from different countries can be genetically subdivided, 
depending on their geographic origin. For instance, the 
DQA 1 locus has been found to be diploid in some CTVT 
samples and haploid in others. In addition, two genetic 
subgroups based on mitochondrial DNA analysis have 
been characterized [5]. Moreover, a mutation found in 
position 963 of the TP53 gene in CTVT cells from Asian 
dogs [2], was absent in tumor samples from Mexican dogs 
[10]. Taken together, these data suggest the existence of 
several CTVT subgroups, probably because of the acquisition 
of new genetic alterations after the development of the 
original CTVT clone. 
The TP53 gene is one of the most important suppressor 
genes associated with cancer development [11]. This gene 
represents a mutation hot spot in the mammalian genome 
and could be used as a marker of genetic diversity. To 
determine the presence of different subgroups of CTVT in 
Mexican dogs, 9 out of the 11 exons in the TP53 gene were 
sequenced in 5 CTVT samples.  Four new polymorphisms 
were found. Considering the clonal origin of CTVT and the 
presence of various mutations in the TP53 gene, our data 
suggested that CTVT samples from different countries 
could be subgrouped based on TP53 polymorphisms. 
All sample tumors were diagnosed by means of 
histopathology, using a hematoxylin and eosin stain and 
molecular diagnosis by PCR-identification of LINE 
insertion in c-myc oncogene, according to Liao et al. [4]. 
RNA was obtained from both 50 mg of fresh frozen 
tumors and 500 μL of total blood using trizol reagent 
(Invitrogen, USA) according to the manufacturer’s 
instructions. Blood and tumor biopsies were always 
obtained from the same dogs. The amplification of exons 
1-9 of TP53 gene was carried out by the one step RT-PCR 
system. Briefly, 1 ng of RNA was amplified using 25 μL of 
buffer 5×, 250 ng/μL of each primer previously designed in 
our laboratory JSTVT1F 5´CAGTCAGAGCTCAATATC 
GACCCCC3´ and JSTVT10R 5´AGGCAGTGCTCGCT 
TGGTAC3´, 1.0 μL/ 5 U of RT, and 5 μL of RNA. 
The PCR purified products were cloned into the pGEM-T 354    Abel Sánchez-Servín et al.
Fig. 1. (A) Electropherograms of the sequence of the TP53 from canine transmissible venereal tumor (CTVT) samples, which show 
changes. Black arrows mark the change in nucleotides. (B) In the sequence alignment of the TP53 from CTVT samples, the nucleotide
changes are marked in bold type.  In the 5 samples of CTVT analyzed are observed four different mutations, producing three different
alleles in the TP53 gene.
Table 1. Characteristics of the mutations identified in samples of canine transmissible venereal tumor and genetic subgroups assigned
Sample Exon Codon Mutation Amino-acid substitution Sub-group assigned References
1
2-3
4
5
*
-----
3
6
2, 6
9
------
49
209
28, 227
316
------
C147G
A625G
A83G, A680G
T964C
None
None
Lys-Gln
None, Ser-Asp
Phe-Ser
1 (Wild Type)
2
3
4
5
This article and [11]
This article 
This article
This article
[2]
vector system (Promega, USA). Briefly, 2 mg of 
recombinant plasmids were used for the sequencing 
reaction with Big Dye Terminator v.3.1 cycle sequencing 
kit (Applied Biosystems, USA); sequencing reaction was 
performed in an ABI PRISM 3100 Sequence Detection 
System (Applied Biosystems, USA). The sequences obtained 
from CTVT samples were aligned with the sequences from 
blood samples and the reported sequence of the wild type 
TP53 gene in the Gen Bank (U62133), using Clustal W 
(DDBJ, Japan). The amino acid translation was performed 
using the Translate tool software found at the expasy tools 
site and the posterior alignment using Clustal W.
After analyzing the five CTVT samples, 4 different 
mutations were found. Only one of the studied samples 
matched 100% with the wild type sequence. A G to C 
transversion was identified in position 147 in two different 
samples, which did not affect the coded amino acid; as well 
as an A to G transition at nucleotide 625 in only one 
sample, which produced a change from glutamic acid to 
lysine at the 209 residue. In a fourth sample, the same kind 
of mutation was found, a G to A transition in two different 
positions, 83 and 680, respectively. The two last mutations 
produced an amino acid change from serine to asparagine 
(Table 1 and Fig. 1).
In the present study we found three different alleles in the 
TP53 gene in 5 samples of CTVT with the same 
histopathological characteristics and the Line/c-myc insertion. 
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variant previously determined by Choi and Kim [2]. Our 
findings suggest that after the ancestral origin of the CTVT, 
the tumors have diverged into several different clones. 
Considering the TP53 mutations that were found, the 
CTVT tumor population could be further classified in at 
least five subgroups. However, in order to identify new alleles, 
determine their frequency and analyze the correlation 
between mutations and geographic regions, it is important 
to increase the number of samples for study and to obtain 
tumor samples from different countries around the world.
Given the important role played by TP53 in the 
maintenance of genome stability, cell cycle regulation, 
apoptosis and senescence, functional polymorphisms in 
this gene could deeply affect cancer development [6]. At 
present, more than 10 mutations in TP53 have been found 
in different canine neoplasias [9]. Although no polymorphisms 
of TP53 gene have been associated with CTVT tumorigenesis. 
This work shows that analyzed samples of CTVT present 
genetic diversity, probably as a result of the proliferation of 
CTVT cells. In future studies it would be important to 
establish if the polymorphisms originating in CTVT play 
an important role in the pathogenesis and response to 
chemotherapy of the disease.
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